Stock Market Watch

Achillion Pharma reports preliminary Phase 1b proof-of-concept data with ACH-2928 NS5A inhibitor for the treatment of Hepatitis C

by ·




Aluminum Corp. of China Limited (ADR) (NYSE:ACH)  is a producer of alumina, primary aluminum and aluminum fabrication in the People’s Republic of China.

The Company is engaged in mining of bauxite, manufacture and distribution of alumina, primary aluminum and aluminum fabrication products, as well as trading of non-ferrous metal products sourced from external suppliers. The scope of business of the Group includes the development of bauxite-related resources, the production, fabrication and distribution of bauxite, carbon and other smelted products. The Company operates in four segments: alumina, primary aluminium, aluminum fabrication and trading.

Company reports proof-of-concept data from its Phase 1b clinical trial of ACH-2928, a first-generation NS5A inhibitor, demonstrating that patients treated with ACH-2928 achieved a mean maximum 3.68 log10 reduction in HCV RNA after three-day monotherapy of 60 mg once daily.


The compound also demonstrated good safety and tolerability both in healthy volunteers and in patients with chronic hepatitis C. Preliminary data from the SAD trial segment demonstrated ACH-2928 was well tolerated at all doses evaluated up to and including the maximum dose of 500 mg.

There were no serious adverse events, no clinically significant changes in vital signs, electrocardiograms, or laboratory evaluations. All reported adverse events were classified as mild or moderate, and were transient in nature.

In parallel, co is advancing its second generation NS5A inhibitor ACH-3102 through IND-enabling studies and the Company expects to initiate clinical development during the first half of 2012.

More Posts by this author

edliston
Post Written By: Ed Liston

Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing in his yacht.


Tags:

Ed Liston

Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing.

You may also like...